Zoetis Inc. to Post Q2 2024 Earnings of $1.51 Per Share, Zacks Research Forecasts (NYSE:ZTS)

Zoetis Inc. (NYSE:ZTS) – Stock analysts at Zacks Research increased their Q2 2024 earnings per share estimates for shares of Zoetis in a report issued on Tuesday, April 9th. Zacks Research analyst E. Bagri now anticipates that the company will post earnings per share of $1.51 for the quarter, up from their prior estimate of $1.50. The consensus estimate for Zoetis’ current full-year earnings is $5.80 per share. Zacks Research also issued estimates for Zoetis’ Q3 2024 earnings at $1.49 EPS, FY2024 earnings at $5.82 EPS, Q2 2025 earnings at $1.64 EPS and Q3 2025 earnings at $1.68 EPS.

Other equities analysts also recently issued reports about the stock. Barclays upped their target price on shares of Zoetis from $255.00 to $260.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 14th. The Goldman Sachs Group increased their price objective on Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research note on Wednesday, January 17th. Piper Sandler raised their price objective on Zoetis from $215.00 to $220.00 and gave the stock an “overweight” rating in a report on Tuesday, February 20th. Jefferies Financial Group reiterated a “buy” rating and issued a $230.00 target price on shares of Zoetis in a report on Tuesday, December 19th. Finally, StockNews.com downgraded Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $224.88.

Zoetis Trading Down 0.3 %

ZTS stock opened at $162.72 on Thursday. The company has a market capitalization of $74.42 billion, a PE ratio of 32.09, a P/E/G ratio of 2.53 and a beta of 0.85. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.36 and a quick ratio of 2.00. Zoetis has a 12 month low of $151.03 and a 12 month high of $201.92. The firm’s 50-day moving average is $180.70 and its 200 day moving average is $181.03.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, February 13th. The company reported $1.24 earnings per share for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). The business had revenue of $2.21 billion during the quarter, compared to analysts’ expectations of $2.19 billion. Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The business’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.15 EPS.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be paid a $0.432 dividend. The ex-dividend date is Thursday, April 18th. This represents a $1.73 annualized dividend and a yield of 1.06%. Zoetis’s dividend payout ratio (DPR) is 33.93%.

Insider Buying and Selling at Zoetis

In other news, EVP Roxanne Lagano sold 923 shares of the company’s stock in a transaction on Thursday, January 18th. The stock was sold at an average price of $191.43, for a total transaction of $176,689.89. Following the transaction, the executive vice president now directly owns 17,569 shares of the company’s stock, valued at $3,363,233.67. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders sold a total of 2,209 shares of company stock worth $408,453 over the last three months. Corporate insiders own 0.12% of the company’s stock.

Institutional Investors Weigh In On Zoetis

Several institutional investors have recently added to or reduced their stakes in the business. Blue Bell Private Wealth Management LLC boosted its stake in Zoetis by 222.5% in the 4th quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock worth $25,000 after purchasing an additional 89 shares in the last quarter. Evermay Wealth Management LLC raised its holdings in shares of Zoetis by 439.3% in the first quarter. Evermay Wealth Management LLC now owns 151 shares of the company’s stock worth $25,000 after buying an additional 123 shares during the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC raised its holdings in shares of Zoetis by 430.8% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock worth $26,000 after buying an additional 112 shares during the last quarter. Worth Asset Management LLC acquired a new stake in shares of Zoetis during the first quarter worth $26,000. Finally, VisionPoint Advisory Group LLC purchased a new stake in shares of Zoetis during the second quarter valued at $29,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.